• Prescribing Information
  • Medical Information
  • CDC* Recommendations​​​​​​2

    CDC guidelines support MenB vaccination for 16 year olds​​​​​​​

    ACIP recommends that a MenB vaccine series may be administered to healthy adolescents and young adults aged 16 through 23 years to provide short-term protection against most strains of MenB. The preferred age for MenB vaccination is 16 through 18 years. The decision to vaccinate should be made based on shared clinical decision-making.2

    The Affordable Care Act mandates insurance coverage for all vaccinations administered in accordance with ACIP recommendations. Health care providers should contact their individual plan to determine specific coverage and reimbursement requirements and adoption timeframes.4 MenB vaccines are available through the Vaccines for Children program.3​​​​​​​
    ​​​​​​​

    More information from ACIP​​​​​​​

    Find out more

    More information from the CDC*

    Find out more

    CDC's Vaccine Information Statement on MenB

    Download

    Individuals at increased risk for MenB should be vaccinated, according to ACIP5

    ACIP recommends certain persons aged ≥10 years who are at increased risk for meningococcal disease should receive MenB vaccine. These persons include:​​​​​​​​​​​​​​​​​​​​​

    • Persons who are in a MenB outbreak situation or at increased risk for meningococcal disease
    • Persons with persistent complement component deficiencies§
    • Persons with anatomic or functional asplenia, including sickle cell disease
    • Microbiologists routinely exposed to isolates of Neisseria meningitidis

    The American Academy of Pediatrics
    ​​​​​​​
    ​​​​​​​​​​​Encourages pediatricians to discuss the availability of MenB vaccines with families, and the decision should be documented if the vaccine is not administered4​​​​​​​

    What is MenB?

    MenB is uncommon, but potentially fatal, and early symptoms may seem like the flu6,7​​​​​​​

    Learn more about MenB

       *CDC=Centers for Disease Control and Prevention.

       If at increased risk of disease or based on discussion with patient's family.

       ACIP=Advisory Committee on Immunization Practices.

       §Including inherited or chronic deficiencies in C3, C5-9, properdin, factor D, factor H, or who are taking eculizumab (Soliris®, Alexion Pharmaceuticals, Inc).​​​​​​
    ​​​​​​​

    Contact your Pfizer Representative or call a Vaccine Specialist at
    ​​​​​​​1-844-439-2571.


    References:
    1. Trumenba [prescribing information]. Philadelphia, PA: Pfizer Inc; 2019.
    2. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices. Recommended immunization schedule for children and adolescents aged 18 years or younger, United States, 2020. Centers for Disease Control and Prevention website. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf. Accessed July 6, 2020.
    3. Centers for Disease Control and Prevention. Charter of the Advisory Committee on Immunization Practices. http://www.cdc.gov/vaccines/acip/committee/acip-charter-2016.pdf. Published April 2016. Accessed July 6, 2020.
    4. The Center for Consumer Information & Insurance Oversight. Affordable Care Act implementation FAQs-set 12. CMS.gov website. http://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs/aca_implementation_faqs12.html. Accessed July 6, 2020.
    5. Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR. Use of serogroup B meningococcal vaccines in persons aged ≥ 10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):608-612.
    6. American Academy of Pediatrics. Recommendations for serogroup B meningococcal vaccine for persons 10 years and older. American Academy of Pediatrics website. http://pediatrics.aappublications.org/content/pediatrics/138/3/e20161890.full.pdf. Accessed July 6, 2020.
    7. Soeters HM, McNamara LA, Whaley M, et al. Serogroup B meningococcal disease outbreak and carriage evaluation at a college—Rhode Island, 2015. MMWR. 2015;64(22):606-607.

    About

    • How TRUMENBA Works
    • Tru Patient Stories
    • Are Your Patients Protected?
    • CDC Recommendations

    Pfizer TruSupport

    • If the second dose is administered earlier than 6 months after the first dose, a third dose should be administered at least 4 months after the second dose1 

    • Ordering options
    • Patient coverage confirmation
    • Essential tools
    • Resources for your practice
    Find out about TruSupport

    TRUMENBA clinical studies

    TRUMENBA is the only MenB vaccine that demonstrated cross-coverage of diverse MenB strains1

    See the data

    The science behind TRUMENBA

    Only TRUMENBA targets both subfamilies, A and B, of fHBP.1

    See the science

    Indication

    • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
    • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis serogroup B strains has not been confirmed
    • Severe allergic reaction after a previous dose of Trumenba is a contraindication
    • Some individuals with altered immunocompetence may have reduced immune responses to Trumenba
    • Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with Trumenba
    • As with any vaccine, vaccination with Trumenba may not protect all vaccine recipients against N meningitidis serogroup B infections
    • Syncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. Procedures should be in place to avoid injury from fainting
    • In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%). Nausea was reported in up to 24% of adolescents in early phase studies
    • Sufficient data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
    • Safety and effectiveness have not been established in pregnant women
    • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
    • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis serogroup B strains has not been confirmed

    Please see full Prescribing Information.​​​​​​​